Relationship among PS2 protein expression, estrogen and progesterone receptor status, and prognosis of breast cancer
Jingxian Liu, Jiyou Li, He Luowen, Zhao Yajuan
Abstract
Jingxian Liu, Jiyou Li, He Luowen, Zhao Yajuan
Abstract
Objective: To study the relationship between the expression of PS 2 protein and Estrogen (ER) and Progesterone Receptor (PR) status and their prognotic value in breast cancer. Methods: Using the immunohistochemical method, PS 2 protein expressions were detected in 105 cases with breast cancer. Results: The positive rate of PS 2 protein was 50.48% (53/105) in 105 cases. The positive rate of PS 2 in the patients who survived five years or more was 56.96% (45/79), which was higher than that of those who lived less than five years (30.77%, 8/26). In the ER, PR (+) patients, the positive rate of PS 2 was higher (76.74%, 33/34), than that of those with ER, PR (−) (22.5%, 9/40). Conclusions: Our results suggest that the expression of PS 2 protein was positively correlated with the 5-year-survival and that of ER and PR in breast cancer. It is considered that PS 2 may be as a prognostic predictor, and detection of PS 2 protein expression was useful for a guiding treatment of breast cancer.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective: To study the relationship between the expression of PS 2 protein and Estrogen (ER) and Progesterone Receptor (PR) status and their prognotic value in breast cancer. Methods: Using the immunohistochemical method, PS 2 protein expressions were detected in 105 cases with breast cancer. Results: The positive rate of PS 2 protein was 50.48% (53/105) in 105 cases. The positive rate of PS 2 in the patients who survived five years or more was 56.96% (45/79), which was higher than that of those who lived less than five years (30.77%, 8/26). In the ER, PR (+) patients, the positive rate of PS 2 was higher (76.74%, 33/34), than that of those with ER, PR (−) (22.5%, 9/40). Conclusions: Our results suggest that the expression of PS 2 protein was positively correlated with the 5-year-survival and that of ER and PR in breast cancer. It is considered that PS 2 may be as a prognostic predictor, and detection of PS 2 protein expression was useful for a guiding treatment of breast cancer.
Key concepts: Breast cancer, Progesterone receptor, Immunohistochemistry, Estrogen receptor, Medicine, Internal medicine, Estrogen, Protein expression